2024
Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer
Justice A, Tate J, Howland F, Gaziano J, Kelley M, McMahon B, Haiman C, Wadia R, Madduri R, Danciu I, Leppert J, Leapman M, Thurtle D, Gnanapragasam V. Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer. European Urology Oncology 2024, 7: 923-932. PMID: 38171965, DOI: 10.1016/j.euo.2023.11.023.Peer-Reviewed Original ResearchVeterans Health AdministrationCharlson Comorbidity IndexNon-prostate cancer mortalityProstate cancer mortalityNonmetastatic prostate cancerComorbidity indexCancer mortalityProvider estimationProstate cancerHealth AdministrationUS Veterans Health AdministrationElectronic health record-based toolsYear of diagnosisRisk of deathObservational cohortMedian ageNonmetastatic cancerPredicting MortalityC-statisticHispanic ethnicityTreatment groupsMortalityCancerNational validationAge
2021
The shifting age distribution of people with HIV using antiretroviral therapy in the United States
Althoff KN, Stewart CN, Humes E, Zhang J, Gerace L, Boyd CM, Wong C, Justice AC, Gebo KA, Thorne JE, Rubtsova AA, Horberg MA, Silverberg MJ, Leng SX, Rebeiro PF, Moore RD, Buchacz K, Kasaie P. The shifting age distribution of people with HIV using antiretroviral therapy in the United States. AIDS 2021, 36: 459-471. PMID: 34750289, PMCID: PMC8795488, DOI: 10.1097/qad.0000000000003128.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyRace/ethnicityNorth American AIDS Cohort CollaborationHIV acquisition riskHIV Epidemic goalsOverall median ageSubgroups of sexRelative reductionAge distributionCohort CollaborationHIV diagnosisMedian ageRisk groupsUS CentersAcquisition riskHIVUS populationDisease controlSurveillance reportsDiscrimination and Calibration of the Veterans Aging Cohort Study Index 2.0 for Predicting Mortality Among People With Human Immunodeficiency Virus in North America
McGinnis KA, Justice AC, Moore RD, Silverberg MJ, Althoff KN, Karris M, Lima VD, Crane HM, Horberg MA, Klein MB, Gange SJ, Gebo KA, Mayor A, Tate JP, Benson C, Bosch R, Kirk G, Marconi V, Colasanti J, Mayer K, Grasso C, Hogg R, Lima V, Montaner J, Sereda P, Salters K, Buchacz K, Li J, Gebo K, Moore R, Moore R, Jacobson J, Horberg M, Silverberg M, Thorne J, Brown T, Tien P, D’Souza G, Smith G, Loutfy M, Gupta M, Klein M, Rabkin C, Kroch A, Burchell A, Betts A, Lindsay J, Nijhawan A, Mayor A, Gill M, Martin J, Li J, Brooks J, Saag M, Mugavero M, Willig J, Bamford L, Karris M, Eron J, Napravnik S, Kitahata M, Crane H, Sterling T, Haas D, Rebeiro P, Turner M, McGinnis K, Justice A, Moore R, Althoff K, Gange S, Kitahata M, Lee J, Saag M, Horberg M, Klein M, McKaig R, Freeman A, Moore R, Althoff K, Freeman A, Kitahata M, Van Rompaey S, Crane H, Morton L, McReynolds J, Lober W, Gange S, Lee J, Hogan B, You B, Humes E, Gerace L, Stewart C, Coburn S. Discrimination and Calibration of the Veterans Aging Cohort Study Index 2.0 for Predicting Mortality Among People With Human Immunodeficiency Virus in North America. Clinical Infectious Diseases 2021, 75: 297-304. PMID: 34609485, PMCID: PMC9410720, DOI: 10.1093/cid/ciab883.Peer-Reviewed Original ResearchConceptsNorth American AIDS Cohort CollaborationVACS Index 2.0National Death IndexHIV-1 RNAHuman immunodeficiency virusCopies/mLRisk of mortalityRace/ethnicityCohort CollaborationNA-ACCORDCause mortalityCD4 countMedian ageDeath IndexImmunodeficiency virusPredicting MortalityMortality ascertainmentMortality rateMortalitySpecific biomarkersPWHDiverse cohortObserved mortalityCohortHIVChange in Alcohol Use Based on Self-Report and a Quantitative Biomarker, Phosphatidylethanol, in People With HIV
McGinnis KA, Tate JP, Bryant KJ, Justice AC, O’Connor P, Rodriguez-Barradas MC, Crystal S, Cutter CJ, Hansen NB, Maisto SA, Marconi VC, Williams EC, Cook RL, Gordon AJ, Gordon KS, Eyawo O, Edelman EJ, Fiellin DA. Change in Alcohol Use Based on Self-Report and a Quantitative Biomarker, Phosphatidylethanol, in People With HIV. AIDS And Behavior 2021, 26: 786-794. PMID: 34542779, DOI: 10.1007/s10461-021-03438-y.Peer-Reviewed Original Research
2020
Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis
McGinnis KA, Skanderson M, Edelman EJ, Gordon AJ, Korthuis PT, Oldfield B, Williams EC, Wyse J, Bryant K, Fiellin DA, Justice AC, Kraemer KL. Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis. Drug And Alcohol Dependence 2020, 217: 108272. PMID: 32971391, PMCID: PMC7757793, DOI: 10.1016/j.drugalcdep.2020.108272.Peer-Reviewed Original ResearchConceptsAlcohol use disorderDetectable VLVisits/monthUse disordersVeterans Aging Cohort Study (VACS) dataCohort study dataRace/ethnicityUndetectable VLMedian ageTreatment initiationMedication treatmentImproved adherenceHIVBehavioral treatmentFirst monthIntensity groupTreatment intensityMonthsImpact of BehavioralOutcomesLinear regression modelsLongitudinal analysisVisitsVLAdherencePredicting prostate cancer death among 98,994 veterans: Differences by race/ethnicity.
Janet T, Danciu I, Justice A, Leapman M, McMahon B, Wadia R. Predicting prostate cancer death among 98,994 veterans: Differences by race/ethnicity. Journal Of Clinical Oncology 2020, 38: e17609-e17609. DOI: 10.1200/jco.2020.38.15_suppl.e17609.Peer-Reviewed Original ResearchProstate cancer deathNon-Hispanic blacksNon-Hispanic whitesVeterans Affairs Healthcare SystemRace/ethnicityHazard ratioGleason scoreCancer deathProstate cancerU.S. Veterans Affairs healthcare systemProstate cancer disease progressionDistant metastatic diseaseProstate cancer mortalityCancer disease progressionLocalized diseasePSA levelsMedian ageMetastatic diseaseLymph nodesPrognostic indexCancer mortalityTumor stageDisease progressionCox modelAge strataInsights Provided by Depression Screening Regarding Pain, Anxiety, and Substance use in a Veteran Population
Stevens ER, Mazumdar M, Caniglia EC, Khan MR, Young KE, Edelman EJ, Gordon AJ, Fiellin DA, Maisto SA, Chichetto NE, Crystal S, Gaither JR, Justice AC, Braithwaite RS. Insights Provided by Depression Screening Regarding Pain, Anxiety, and Substance use in a Veteran Population. Journal Of Primary Care & Community Health 2020, 11: 2150132720949123. PMID: 32772883, PMCID: PMC7418233, DOI: 10.1177/2150132720949123.Peer-Reviewed Original ResearchConceptsPositive predictive valueSubstance useOdds ratioVeterans Aging Cohort Study (VACS) dataPHQ-9 scoresPrimary care settingCohort study dataTest performance characteristicsSymptoms of anxietyMedian ageDepression screeningLikelihood ratio valuesDepression screenPHQ-9Care settingsVeteran populationPredictive valueSignificant associationSymptomsDiagnostic assessmentAnxietyStudy dataAdditional informationAssociationPain
2018
Duration of opioid prescriptions predicts incident nonmedical use of prescription opioids among U.S. veterans receiving medical care
Barry DT, Marshall BDL, Becker WC, Gordon AJ, Crystal S, Kerns RD, Gaither JR, Gordon KS, Justice AC, Fiellin DA, Edelman EJ. Duration of opioid prescriptions predicts incident nonmedical use of prescription opioids among U.S. veterans receiving medical care. Drug And Alcohol Dependence 2018, 191: 348-354. PMID: 30176548, PMCID: PMC6596307, DOI: 10.1016/j.drugalcdep.2018.07.008.Peer-Reviewed Original ResearchConceptsPrescription opioid receiptPrescription opioidsMedical careOpioid receiptVeterans Health Administration primary careNonmedical useMultivariable Cox modelInfectious disease clinicProspective cohort studyProportional hazards regressionPrescription opioid medicationsPublic health problemSubstance use disordersMedication-related characteristicsOpioid therapyOpioid medicationsOpioid prescriptionsCohort studyDisease clinicMedian ageHazards regressionEligible participantsPrimary careRisk factorsIncidence rate
2017
Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older
Lodi S, Costagliola D, Sabin C, del Amo J, Logan R, Abgrall S, Reiss P, van Sighem A, Jose S, Blanco JR, Hernando V, Bucher HC, Kovari H, Segura F, Ambrosioni J, Gogos CA, Pantazis N, Dabis F, Vandenhende MA, Meyer L, Seng R, Gill MJ, Krentz H, Phillips AN, Porter K, Grinsztejn B, Pacheco AG, Muga R, Tate J, Justice A, Hernán MA. Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 76: 311-318. PMID: 28746165, PMCID: PMC5704899, DOI: 10.1097/qai.0000000000001498.Peer-Reviewed Original ResearchConceptsGeneral HIV populationImmediate initiationHIV populationCD4 countCells/US veteransAIDS mortalityAIDS-free individualsNon-AIDS mortalityUS Veteran cohortHIV-positive individualsHIV-CAUSAL CollaborationAntiretroviral therapyCause mortalityAntiretroviral treatmentMedian ageClinical guidelinesVeteran cohortHigh mortalityMortalityCD4Younger participantsRiskBaselineVeteransHIV Infection, Immunosuppression, and Age at Diagnosis of Non-AIDS-Defining Cancers
Shiels MS, Althoff KN, Pfeiffer RM, Achenbach CJ, Abraham AG, Castilho J, Cescon A, D’Souza G, Dubrow R, Eron JJ, Gebo K, Gill M, Goedert JJ, Grover S, Hessol NA, Justice A, Kitahata M, Mayor A, Moore RD, Napravnik S, Novak RM, Thorne JE, Silverberg MJ, Engels EA, AIDS F. HIV Infection, Immunosuppression, and Age at Diagnosis of Non-AIDS-Defining Cancers. Clinical Infectious Diseases 2017, 64: 468-475. PMID: 27940936, PMCID: PMC5850313, DOI: 10.1093/cid/ciw764.Peer-Reviewed Original ResearchConceptsOral cavity/pharynxYounger ageCancer diagnosisCD4 countMedian ageLung cancerKidney cancerGeneral populationNorth American AIDS Cohort CollaborationMost cancersEnd Results ProgramHuman immunodeficiency virusRisk factor exposureLung cancer diagnosisAccelerated cancer progressionCohort CollaborationNon-AIDSAnal cancerHIV infectionImmunodeficiency virusResults ProgramMyeloma diagnosisPLWHAIDS statusCancer
2015
Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada
Koethe JR, Jenkins CA, Lau B, Shepherd BE, Justice AC, Tate JP, Buchacz K, Napravnik S, Mayor AM, Horberg MA, Blashill AJ, Willig A, Wester CW, Silverberg MJ, Gill J, Thorne JE, Klein M, Eron JJ, Kitahata MM, Sterling TR, Moore RD. Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. AIDS Research And Human Retroviruses 2015, 32: 50-58. PMID: 26352511, PMCID: PMC4692122, DOI: 10.1089/aid.2015.0147.Peer-Reviewed Original ResearchConceptsYears of ARTBody mass indexAntiretroviral therapyART initiationMedian body mass indexNormal body mass indexHigher body mass indexWeight gainWhite womenUnited States National HealthART-exposed HIVHIV-1 RNAProportion of overweightMultivariable linear regressionCohort CollaborationNA-ACCORDNon-white womenCohort studyMedian ageObese adultsMass indexObesity prevalenceNational HealthHigh prevalenceHealth complications
2014
Comparison of Risk and Age at Diagnosis of Myocardial Infarction, End-Stage Renal Disease, and Non-AIDS-Defining Cancer in HIV-Infected Versus Uninfected Adults
Althoff KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, Rimland D, Rodriguez-Barradas MC, Dubrow R, Park LS, Skanderson M, Shiels MS, Gange SJ, Gebo KA, Justice AC. Comparison of Risk and Age at Diagnosis of Myocardial Infarction, End-Stage Renal Disease, and Non-AIDS-Defining Cancer in HIV-Infected Versus Uninfected Adults. Clinical Infectious Diseases 2014, 60: 627-638. PMID: 25362204, PMCID: PMC4318916, DOI: 10.1093/cid/ciu869.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseMyocardial infarctionUninfected adultsAge-associated eventsRenal diseaseHIV statusIncident diagnosisMean ageVeterans Aging Cohort StudyGreater riskCox proportional hazards modelAging Cohort StudyHuman immunodeficiency virusProportional hazards modelNon-AIDSUninfected veteransCohort studyMultivariate linear regression modelMedian ageComparison of risksImmunodeficiency virusAge-associated diseasesImportant confoundersHigh riskHazards model
2011
Hepatic Safety and Antiretroviral Effectiveness in HIV‐Infected Patients Receiving Naltrexone
Tetrault JM, Tate JP, McGinnis KA, Goulet JL, Sullivan LE, Bryant K, Justice AC, Fiellin DA, Team F. Hepatic Safety and Antiretroviral Effectiveness in HIV‐Infected Patients Receiving Naltrexone. Alcohol Clinical And Experimental Research 2011, 36: 318-324. PMID: 21797892, PMCID: PMC3221963, DOI: 10.1111/j.1530-0277.2011.01601.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlanine TransaminaseAlcoholismAntiretroviral Therapy, Highly ActiveAspartate AminotransferasesCD4 Lymphocyte CountChemical and Drug Induced Liver InjuryCohort StudiesDatabases, FactualDrug InteractionsDrug-Related Side Effects and Adverse ReactionsFemaleHIV InfectionsHumansLiverLiver Function TestsMaleMiddle AgedNaltrexoneNarcotic AntagonistsOpioid-Related DisordersRNA, ViralVeteransConceptsNaltrexone prescriptionAlanine aminotransferaseOpioid dependenceVeterans Aging Cohort Study Virtual CohortAspartate aminotransferaseImpact of naltrexoneSignificant alanine aminotransferaseLiver enzyme elevationMean CD4 countHIV-infected individualsAST changesHepatic safetyHIV biomarkersOral naltrexoneCD4 countHIV RNAMedian durationEnzyme elevationMedian ageAST levelsNaltrexone useHepatic enzymesAntiretroviral effectivenessHIVPatients
2010
Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada
Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Justice AC, Gebo KA, Eron JJ, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Calzavara LM, Deeks SG, Martin JN, Rachlis AR, Napravnik S, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Kushel M, Goedert JJ, McKaig RG, Van Rompaey SE, Zhang J, Moore RD, Research and Design N. Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada. Clinical Infectious Diseases 2010, 50: 1512-1520. PMID: 20415573, PMCID: PMC2862849, DOI: 10.1086/652650.Peer-Reviewed Original ResearchConceptsMean CD4 countPercentage of patientsHIV transmission riskCD4 countHIV careFirst presentationTransmission riskCells/North American AIDS Cohort CollaborationHuman immunodeficiency virus (HIV) careHuman immunodeficiency virus (HIV) servicesHeterosexual transmission riskMedian CD4 countEarly HIV diagnosisT-lymphocyte countsHIV RNA measurementsHistory of AIDSRace/ethnicityAntiretroviral exposureCohort CollaborationHIV diagnosisLymphocyte countInitial presentationMedian ageLate presentationRefill Adherence to Oral Hypoglycemic Agents and Glycemic Control in Veterans
Kim N, Agostini JV, Justice AC. Refill Adherence to Oral Hypoglycemic Agents and Glycemic Control in Veterans. Annals Of Pharmacotherapy 2010, 44: 800-808. PMID: 20388863, PMCID: PMC3117591, DOI: 10.1345/aph.1m570.Peer-Reviewed Original ResearchConceptsOral hypoglycemic agentsGlycemic controlGoal A1CHypoglycemic agentsBaseline dateInadequate diabetes controlPercent of patientsPoor glycemic controlMain outcome measuresBaseline A1CContinuous refillNonpersistent patientsComorbid hypertensionDiabetes medicationsMedian ageBetter persistenceMedication nonadherenceDiabetes controlDays' supplyOutcome measuresClinical careEligible veteransPatientsA1CMedications
2009
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries
Zwahlen M, Harris R, May M, Hogg R, Costagliola D, de Wolf F, Gill J, Fätkenheuer G, Lewden C, Saag M, Staszewski S, d'Arminio Monforte A, Casabona J, Lampe F, Justice A, von Wyl V, Egger M. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. International Journal Of Epidemiology 2009, 38: 1624-1633. PMID: 19820106, PMCID: PMC3119390, DOI: 10.1093/ije/dyp306.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCause of DeathCD4 Lymphocyte CountCohort StudiesFemaleHIVHIV InfectionsHomosexuality, MaleHumansMaleMortalityPrevalenceProspective StudiesRisk FactorsSubstance Abuse, IntravenousViral LoadVirus ReplicationConceptsCD4 cell countAntiretroviral therapyCells/microLGeneral populationCell countEligible patientsExcess mortalityCopies/Start of ARTViral replicationART Cohort CollaborationCorresponding general populationMortality of HIVPotent antiretroviral therapyCombination antiretroviral therapyPercentage of patientsProspective cohort studyInjection drug useViral load measurementsNumber of deathsCohort CollaborationCohort studyMedian ageViral loadClinical stageMeasuring Persistence to Oral Hypoglycemic Agents in Type 2 Diabetic Veterans
Kim N, Agostini J, Justice A. Measuring Persistence to Oral Hypoglycemic Agents in Type 2 Diabetic Veterans. Journal Of Pharmacy Technology 2009, 25: 223-229. PMID: 21779543, PMCID: PMC3139220, DOI: 10.1177/875512250902500402.Peer-Reviewed Original ResearchOral hypoglycemic agentsHypoglycemic agentsDiabetic veteransTotal daysStudy entryMedian persistenceKappa agreement statisticsContinuous refillMultiple comorbiditiesMost patientsMedian ageDiabetes controlMedication adherenceInclusion criteriaEligible veteransPoor persistenceSubstantial proportionClinical applicationVeteransPatientsFirst yearAgreement statisticsDaysPrescriptionContinuous fill